Obseva Logo4 (00000002).jpg
ObsEva Announces First Quarter 2021 Financial Results and Business Update
May 06, 2021 01:00 ET | ObsEva SA
  -Yselty® for uterine fibroids: US New Drug Application submission planned in Q3:21; European marketing approval recommendation anticipated in Q4:21- -Yselty® for endometriosis: Readout from...
Obseva Logo4 (00000002).jpg
ObsEva Provides Business Outlook for 2021
February 10, 2021 01:00 ET | ObsEva SA
  GENEVA, Switzerland and BOSTON, MA (February 10, 2021) – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s...
Obseva Logo4 (00000002).jpg
ObsEva SA Reports Positive Topline Results of the PROLONG Proof-of-Concept Trial of Ebopiprant (OBE022) for Treatment of Preterm Labor
November 16, 2020 01:00 ET | ObsEva SA
  Over 50% reduction of pre-term delivery within 48hrs of treatment in singleton pregnancyMaternal, fetal and neonatal safety comparable to placeboData supports advancement of ebopiprant to Phase 2b...